MedKoo Cat#: 208151 | Name: PD-102807
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

In membranes of Chinese hamster ovary cells expressing the cloned human M1-M4 muscarinic receptor subtypes, PD 102807, a novel M4 selective antagonist, was found to counteract the M4 receptor-induced stimulation . PD 102807 interacted with muscarinic receptors in a manner typical of a simple competitive antagonist. These data provide additional evidence that PD 102807 is a M4-receptor preferring antagonist and that this compound can discriminate the striatal muscarinic receptors inhibiting DA D1 receptor activity from the cortical receptors mediating the potentiation of CRH receptor signalling and the inhibition of Ca2+/CaM-stimulated adenylyl cyclase activity.

Chemical Structure

PD-102807
PD-102807
CAS# 23062-91-1

Theoretical Analysis

MedKoo Cat#: 208151

Name: PD-102807

CAS#: 23062-91-1

Chemical Formula: C25H28N2O4

Exact Mass: 420.2049

Molecular Weight: 420.51

Elemental Analysis: C, 71.41; H, 6.71; N, 6.66; O, 15.22

Price and Availability

Size Price Availability Quantity
10mg USD 450.00 2 Weeks
25mg USD 750.00 2 Weeks
50mg USD 1,250.00 2 Weeks
100mg USD 1,950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
23062-91-1
Synonym
PD102807; PD 102807; PD-102807;
IUPAC/Chemical Name
Ethyl (S)-9-methoxy-2-propyl-3,6a,11,14-tetrahydro-12H-indolo[4',5':5,6][1,3]oxazino[2,3-a]isoquinoline-1-carboxylate
InChi Key
JCJXWNVOVZEIHE-DEOSSOPVSA-N
InChi Code
InChI=1S/C25H28N2O4/c1-4-6-19-23(25(28)30-5-2)22-18-14-27-12-11-15-13-16(29-3)7-8-17(15)24(27)31-21(18)10-9-20(22)26-19/h7-10,13,24,26H,4-6,11-12,14H2,1-3H3/t24-/m0/s1
SMILES Code
O=C(C1=C(CCC)NC2=C1C(C3)=C(C=C2)O[C@]4([H])N3CCC5=C4C=CC(OC)=C5)OCC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 420.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Olianas MC, Onali P. PD 102807, a novel muscarinic M4 receptor antagonist, discriminates between striatal and cortical muscarinic receptors coupled to cyclic AMP. Life Sci. 1999;65(21):2233-40. doi: 10.1016/s0024-3205(99)00488-9. PMID: 10576595. 2: Brugnoli A, Pisanò CA, Morari M. Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats. Neurobiol Dis. 2020 Oct;144:105044. doi: 10.1016/j.nbd.2020.105044. Epub 2020 Aug 13. PMID: 32798726. 3: Muramatsu I, Uwada J, Yoshiki H, Sada K, Lee KS, Yazawa T, Taniguchi T, Nishio M, Ishibashi T, Masuoka T. Novel regulatory systems for acetylcholine release in rat striatum and anti-Alzheimer's disease drugs. J Neurochem. 2019 Jun;149(5):605-623. doi: 10.1111/jnc.14701. Epub 2019 May 7. PMID: 30968952. 4: Stoll C, Eltze M, Lambrecht G, Zentner J, Feuerstein TJ, Jackisch R. Functional characterization of muscarinic autoreceptors in rat and human neocortex. J Neurochem. 2009 Aug;110(3):837-47. doi: 10.1111/j.1471-4159.2009.06193.x. Epub 2009 May 29. PMID: 19493162. 5: Pujol Lereis VA, Hita FJ, Gobbi MD, Verdi MG, Rodriguez MC, Rothlin RP. Pharmacological characterization of muscarinic receptor subtypes mediating vasoconstriction of human umbilical vein. Br J Pharmacol. 2006 Mar;147(5):516-23. doi: 10.1038/sj.bjp.0706654. PMID: 16444291; PMCID: PMC1616972. 6: Choppin A, Eglen RM. Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle. Br J Pharmacol. 2001 Feb;132(4):835-42. doi: 10.1038/sj.bjp.0703901. PMID: 11181424; PMCID: PMC1572633. 7: Lau BK, Vaughan CW. Muscarinic modulation of synaptic transmission via endocannabinoid signalling in the rat midbrain periaqueductal gray. Mol Pharmacol. 2008 Nov;74(5):1392-8. doi: 10.1124/mol.108.045872. Epub 2008 Aug 4. PMID: 18678620. 8: Böhme TM, Augelli-Szafran CE, Hallak H, Pugsley T, Serpa K, Schwarz RD. Synthesis and pharmacology of benzoxazines as highly selective antagonists at M(4) muscarinic receptors. J Med Chem. 2002 Jul 4;45(14):3094-102. doi: 10.1021/jm011116o. Erratum in: J Med Chem 2002 Oct 10;45(21):4800. PMID: 12086495. 9: Myslivecek J, Klein M, Novakova M, Ricny J. The detection of the non-M2 muscarinic receptor subtype in the rat heart atria and ventricles. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):103-16. doi: 10.1007/s00210-008-0285-8. Epub 2008 Apr 29. PMID: 18443764. 10: Hogan K, Markos F. Muscarinic type 1 receptors mediate part of nitric oxide's vagal facilitatory effect in the isolated innervated rat right atrium. Nitric Oxide. 2007 Feb;16(1):110-7. doi: 10.1016/j.niox.2006.05.005. Epub 2006 Jun 7. PMID: 16843016.